Embecta Corp. (EMBC) to Issue Quarterly Dividend of $0.01 on September 15th

Embecta Corp. (NASDAQ:EMBC) declared a quarterly dividend on Friday, August 7th. Stockholders of record on Thursday, August 27th will be paid a dividend of 0.01 per share on Tuesday, September 15th. This represents a c) dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, August 27th.

Embecta has a dividend payout ratio of 1.4% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Embecta to earn $1.75 per share next year, which means the company should continue to be able to cover its $0.04 annual dividend with an expected future payout ratio of 2.3%.

Embecta Stock Performance

NASDAQ EMBC opened at $4.42 on Friday. Embecta has a twelve month low of $2.77 and a twelve month high of $15.55. The stock has a market cap of $262.24 million, a PE ratio of 2.99 and a beta of 0.81. The firm has a 50-day simple moving average of $3.34 and a 200 day simple moving average of $6.66.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.29. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The firm had revenue of $271.70 million for the quarter, compared to analyst estimates of $254.53 million. The company’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Research analysts forecast that Embecta will post 1.85 earnings per share for the current fiscal year.

Key Stories Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
• Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
• Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
• Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
• Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
• Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.